Table 3.
Summary of characteristics of men who underwent biopsies after their baseline PSA screen
| Total cohort* | MLH1 carriers | MLH1 non-carrier controls | p value | MSH2 carriers | MSH2 non-carrier controls | p value | MSH6 carriers | MSH6 non-carrier controls | p value | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total biopsies | 35 | 6 | 5 | 18 | 3 | 5 | 2 | |||
| Biopsy compliance | 35/56 (63%) | 6/11 (55%) | 5/10 (50%) | >0·99 | 18/27 (67%) | 3/7 (43%) | 0·39 | 5/5 (100%) | 2/4 (50%) | 0·17 |
| PSA concentration that triggered biopsy, ng/mL | 5·1 (3·80–11·1) | 3·9 (3·5–5·4) | 4·2 (3·6–9·4) | 0·72 | 5·8 (3·8–20·6) | 5·1 (3·4–5·3) | 0·45 | 7·8 (4·0–9·9) | 4·3 (3·4–5·1) | 0·43 |
| Age at biopsy, years | 61 (56–64) | 60 (55–64) | 62 (62–64) | 0·35 | 60 (53–64) | 64 (62–66) | 0·13 | 64 (59–67) | 63 (62–64) | 0·86 |
| Time between PSA screening and biopsy, days | 91 (54–148) | 92 (39–169) | 87 (64–96) | 0·70 | 105 (43–179) | 87 (80–256) | 0·66 | 89 (77–120) | 84 (80–87) | 0·57 |
| Biopsy cores taken | 12 (12–14) | 12 (10–23) | 12 (10–14) | >0·99 | 13 (12–15) | 10 (8–12) | 0·07 | 13 (11–13) | 10 (8–12) | 0·27 |
Data are n, n/N (%), or median (IQR).
*
BRCA1 and BRCA2 non-carrier controls were included in every non-carrier control group but only counted once in the total cohort number; therefore, the sum of each genetic cohort does not equal the total.